HIV  ||| S:0 E:4 ||| NNP
prevalence  ||| S:4 E:15 ||| NN
and  ||| S:15 E:19 ||| CC
factors  ||| S:19 E:27 ||| NNS
associated  ||| S:27 E:38 ||| VBN
with  ||| S:38 E:43 ||| IN
HIV  ||| S:43 E:47 ||| NNP
infection  ||| S:47 E:57 ||| NN
among  ||| S:57 E:63 ||| IN
men  ||| S:63 E:67 ||| NNS
who  ||| S:67 E:71 ||| WP
have  ||| S:71 E:76 ||| VBP
sex  ||| S:76 E:80 ||| NN
with  ||| S:80 E:85 ||| IN
men  ||| S:85 E:89 ||| NNS
in  ||| S:89 E:92 ||| IN
Cameroon  ||| S:92 E:101 ||| NNP
Despite  ||| S:101 E:109 ||| IN
men  ||| S:109 E:113 ||| NNS
who  ||| S:113 E:117 ||| WP
have  ||| S:117 E:122 ||| VBP
sex  ||| S:122 E:126 ||| NN
with  ||| S:126 E:131 ||| IN
men  ||| S:131 E:135 ||| NNS
( ||| S:135 E:136 ||| -LRB-
MSM ||| S:136 E:139 ||| NNP
)  ||| S:139 E:141 ||| -RRB-
being  ||| S:141 E:147 ||| VBG
a  ||| S:147 E:149 ||| DT
key  ||| S:149 E:153 ||| JJ
population  ||| S:153 E:164 ||| NN
for  ||| S:164 E:168 ||| IN
HIV  ||| S:168 E:172 ||| NNP
programming  ||| S:172 E:184 ||| NN
globally ||| S:184 E:192 ||| RB
,  ||| S:192 E:194 ||| ,
HIV  ||| S:194 E:198 ||| NNP
epidemiologic  ||| S:198 E:212 ||| NN
data  ||| S:212 E:217 ||| NNS
on  ||| S:217 E:220 ||| IN
MSM  ||| S:220 E:224 ||| NNP
in  ||| S:224 E:227 ||| IN
Central  ||| S:227 E:235 ||| NNP
Africa  ||| S:235 E:242 ||| NNP
are  ||| S:242 E:246 ||| VBP
sparse ||| S:246 E:252 ||| VBN
.  ||| S:252 E:254 ||| .
We  ||| S:254 E:257 ||| PRP
measured  ||| S:257 E:266 ||| VBD
HIV  ||| S:266 E:270 ||| NNP
and  ||| S:270 E:274 ||| CC
syphilis  ||| S:274 E:283 ||| JJ
prevalence  ||| S:283 E:294 ||| NN
and  ||| S:294 E:298 ||| CC
the  ||| S:298 E:302 ||| DT
factors  ||| S:302 E:310 ||| NNS
associated  ||| S:310 E:321 ||| VBN
with  ||| S:321 E:326 ||| IN
HIV  ||| S:326 E:330 ||| NNP
infection  ||| S:330 E:340 ||| NN
among  ||| S:340 E:346 ||| IN
MSM  ||| S:346 E:350 ||| NNP
in  ||| S:350 E:353 ||| IN
Cameroon ||| S:353 E:361 ||| NNP
.  ||| S:361 E:363 ||| .
Two  ||| S:363 E:367 ||| CD
hundred  ||| S:367 E:375 ||| CD
and  ||| S:375 E:379 ||| CC
seventy-two  ||| S:379 E:391 ||| JJ
and  ||| S:391 E:395 ||| CC
239  ||| S:395 E:399 ||| CD
MSM  ||| S:399 E:403 ||| NNS
aged  ||| S:403 E:408 ||| VBN
≥  ||| S:408 E:410 ||| CD
18  ||| S:410 E:413 ||| CD
from  ||| S:413 E:418 ||| IN
Douala  ||| S:418 E:425 ||| NNP
and  ||| S:425 E:429 ||| CC
Yaoundé ||| S:429 E:436 ||| NNP
,  ||| S:436 E:438 ||| ,
respectively ||| S:438 E:450 ||| RB
,  ||| S:450 E:452 ||| ,
were  ||| S:452 E:457 ||| VBD
recruited  ||| S:457 E:467 ||| VBN
using  ||| S:467 E:473 ||| VBG
respondent-driven  ||| S:473 E:491 ||| JJ
sampling  ||| S:491 E:500 ||| NNS
( ||| S:500 E:501 ||| -LRB-
RDS ||| S:501 E:504 ||| NNP
)  ||| S:504 E:506 ||| -RRB-
for  ||| S:506 E:510 ||| IN
this  ||| S:510 E:515 ||| DT
cross-sectional  ||| S:515 E:531 ||| JJ
surveillance  ||| S:531 E:544 ||| NN
study  ||| S:544 E:550 ||| NN
in  ||| S:550 E:553 ||| IN
2011 ||| S:553 E:557 ||| CD
.  ||| S:557 E:559 ||| .
Participants  ||| S:559 E:572 ||| NNS
completed  ||| S:572 E:582 ||| VBD
a  ||| S:582 E:584 ||| DT
structured  ||| S:584 E:595 ||| JJ
questionnaire  ||| S:595 E:609 ||| NN
and  ||| S:609 E:613 ||| CC
HIV  ||| S:613 E:617 ||| NNP
and  ||| S:617 E:621 ||| CC
syphilis  ||| S:621 E:630 ||| JJ
testing ||| S:630 E:637 ||| NN
.  ||| S:637 E:639 ||| .
Statistical  ||| S:639 E:651 ||| JJ
analyses ||| S:651 E:659 ||| NNS
,  ||| S:659 E:661 ||| ,
including  ||| S:661 E:671 ||| VBG
RDS-weighted  ||| S:671 E:684 ||| JJ
proportions ||| S:684 E:695 ||| NNS
,  ||| S:695 E:697 ||| ,
bootstrapped  ||| S:697 E:710 ||| JJ
confidence  ||| S:710 E:721 ||| NN
intervals  ||| S:721 E:731 ||| NNS
and  ||| S:731 E:735 ||| CC
logistic  ||| S:735 E:744 ||| JJ
regressions ||| S:744 E:755 ||| NN
,  ||| S:755 E:757 ||| ,
were  ||| S:757 E:762 ||| VBD
used ||| S:762 E:766 ||| VBN
.  ||| S:766 E:768 ||| .
Crude  ||| S:768 E:774 ||| JJ
and  ||| S:774 E:778 ||| CC
RDS-weighted  ||| S:778 E:791 ||| NNP
HIV  ||| S:791 E:795 ||| NNP
prevalence  ||| S:795 E:806 ||| NN
were  ||| S:806 E:811 ||| VBD
28.6 ||| S:811 E:815 ||| CD
%  ||| S:815 E:817 ||| NN
( ||| S:817 E:818 ||| -LRB-
73 ||| S:818 E:820 ||| CD
/ ||| S:820 E:821 ||| CD
255 ||| S:821 E:824 ||| CD
)  ||| S:824 E:826 ||| -RRB-
and  ||| S:826 E:830 ||| CC
25.5 ||| S:830 E:834 ||| CD
%  ||| S:834 E:836 ||| NN
( ||| S:836 E:837 ||| -LRB-
95 ||| S:837 E:839 ||| CD
%  ||| S:839 E:841 ||| NN
CI  ||| S:841 E:844 ||| NNP
19.1-31.9 ||| S:844 E:853 ||| NNP
)  ||| S:853 E:855 ||| -RRB-
in  ||| S:855 E:858 ||| IN
Douala ||| S:858 E:864 ||| NNP
,  ||| S:864 E:866 ||| ,
and  ||| S:866 E:870 ||| CC
47.3 ||| S:870 E:874 ||| CD
%  ||| S:874 E:876 ||| NN
( ||| S:876 E:877 ||| -LRB-
98 ||| S:877 E:879 ||| CD
/ ||| S:879 E:880 ||| CD
207 ||| S:880 E:883 ||| CD
)  ||| S:883 E:885 ||| -RRB-
and  ||| S:885 E:889 ||| CC
44.4 ||| S:889 E:893 ||| CD
%  ||| S:893 E:895 ||| NN
( ||| S:895 E:896 ||| -LRB-
95 ||| S:896 E:898 ||| CD
%  ||| S:898 E:900 ||| NN
CI  ||| S:900 E:903 ||| NNP
35.7-53.2 ||| S:903 E:912 ||| NNP
)  ||| S:912 E:914 ||| -RRB-
in  ||| S:914 E:917 ||| IN
Yaoundé ||| S:917 E:924 ||| NNP
.  ||| S:924 E:926 ||| .
Active  ||| S:926 E:933 ||| JJ
syphilis  ||| S:933 E:942 ||| JJ
prevalence  ||| S:942 E:953 ||| NN
in  ||| S:953 E:956 ||| IN
total  ||| S:956 E:962 ||| NN
was  ||| S:962 E:966 ||| VBD
0.4 ||| S:966 E:969 ||| CD
%  ||| S:969 E:971 ||| NN
( ||| S:971 E:972 ||| -LRB-
2 ||| S:972 E:973 ||| CD
/ ||| S:973 E:974 ||| CD
511 ||| S:974 E:977 ||| CD
) ||| S:977 E:978 ||| -RRB-
.  ||| S:978 E:980 ||| .
Overall ||| S:980 E:987 ||| RB
,  ||| S:987 E:989 ||| ,
median  ||| S:989 E:996 ||| JJ
age  ||| S:996 E:1000 ||| NN
was  ||| S:1000 E:1004 ||| VBD
24  ||| S:1004 E:1007 ||| CD
years ||| S:1007 E:1012 ||| NNS
,  ||| S:1012 E:1014 ||| ,
62 ||| S:1014 E:1016 ||| CD
%  ||| S:1016 E:1018 ||| NN
( ||| S:1018 E:1019 ||| -LRB-
317 ||| S:1019 E:1022 ||| CD
/ ||| S:1022 E:1023 ||| CD
511 ||| S:1023 E:1026 ||| CD
)  ||| S:1026 E:1028 ||| -RRB-
of  ||| S:1028 E:1031 ||| IN
MSM  ||| S:1031 E:1035 ||| NNP
identified  ||| S:1035 E:1046 ||| VBD
as  ||| S:1046 E:1049 ||| IN
bisexual  ||| S:1049 E:1058 ||| NN
and  ||| S:1058 E:1062 ||| CC
28.6 ||| S:1062 E:1066 ||| CD
%  ||| S:1066 E:1068 ||| NN
( ||| S:1068 E:1069 ||| -LRB-
144 ||| S:1069 E:1072 ||| CD
/ ||| S:1072 E:1073 ||| CD
511 ||| S:1073 E:1076 ||| CD
)  ||| S:1076 E:1078 ||| -RRB-
identified  ||| S:1078 E:1089 ||| VBN
as  ||| S:1089 E:1092 ||| IN
gay ||| S:1092 E:1095 ||| JJ
.  ||| S:1095 E:1097 ||| .
Inconsistent  ||| S:1097 E:1110 ||| JJ
condom  ||| S:1110 E:1117 ||| NN
use  ||| S:1117 E:1121 ||| NN
with  ||| S:1121 E:1126 ||| IN
regular  ||| S:1126 E:1134 ||| JJ
male  ||| S:1134 E:1139 ||| JJ
partners  ||| S:1139 E:1148 ||| NNS
( ||| S:1148 E:1149 ||| -LRB-
64.1 ||| S:1149 E:1153 ||| CD
% ||| S:1153 E:1154 ||| NN
;  ||| S:1154 E:1156 ||| :
273 ||| S:1156 E:1159 ||| CD
/ ||| S:1159 E:1160 ||| CD
426 ||| S:1160 E:1163 ||| CD
)  ||| S:1163 E:1165 ||| -RRB-
and  ||| S:1165 E:1169 ||| CC
casual  ||| S:1169 E:1176 ||| JJ
male  ||| S:1176 E:1181 ||| NN
and  ||| S:1181 E:1185 ||| CC
female  ||| S:1185 E:1192 ||| JJ
partners  ||| S:1192 E:1201 ||| NNS
( ||| S:1201 E:1202 ||| -LRB-
48.5 ||| S:1202 E:1206 ||| NNP
% ||| S:1206 E:1207 ||| NN
;  ||| S:1207 E:1209 ||| :
195 ||| S:1209 E:1212 ||| CD
/ ||| S:1212 E:1213 ||| CD
402 ||| S:1213 E:1216 ||| CD
)  ||| S:1216 E:1218 ||| -RRB-
was  ||| S:1218 E:1222 ||| VBD
common ||| S:1222 E:1228 ||| JJ
,  ||| S:1228 E:1230 ||| ,
as  ||| S:1230 E:1233 ||| RB
was  ||| S:1233 E:1237 ||| VBD
the  ||| S:1237 E:1241 ||| DT
inconsistent  ||| S:1241 E:1254 ||| JJ
use  ||| S:1254 E:1258 ||| NN
of  ||| S:1258 E:1261 ||| IN
condom-compatible  ||| S:1261 E:1279 ||| JJ
lubricants  ||| S:1279 E:1290 ||| NNS
( ||| S:1290 E:1291 ||| -LRB-
CCLs ||| S:1291 E:1295 ||| NNP
)  ||| S:1295 E:1297 ||| -RRB-
( ||| S:1297 E:1298 ||| -LRB-
26.3 ||| S:1298 E:1302 ||| CD
% ||| S:1302 E:1303 ||| NN
;  ||| S:1303 E:1305 ||| :
124 ||| S:1305 E:1308 ||| CD
/ ||| S:1308 E:1309 ||| CD
472 ||| S:1309 E:1312 ||| CD
) ||| S:1312 E:1313 ||| -RRB-
.  ||| S:1313 E:1315 ||| .
In  ||| S:1315 E:1318 ||| IN
Douala ||| S:1318 E:1324 ||| NNP
,  ||| S:1324 E:1326 ||| ,
preferring  ||| S:1326 E:1337 ||| VBG
a  ||| S:1337 E:1339 ||| DT
receptive  ||| S:1339 E:1349 ||| JJ
sexual  ||| S:1349 E:1356 ||| JJ
role  ||| S:1356 E:1361 ||| NN
was  ||| S:1361 E:1365 ||| VBD
associated  ||| S:1365 E:1376 ||| VBN
with  ||| S:1376 E:1381 ||| IN
prevalent  ||| S:1381 E:1391 ||| JJ
HIV  ||| S:1391 E:1395 ||| NNP
infection  ||| S:1395 E:1405 ||| NN
[ ||| S:1405 E:1406 ||| -LRB-
adjusted  ||| S:1406 E:1415 ||| VBN
odds  ||| S:1415 E:1420 ||| NNS
ratio  ||| S:1420 E:1426 ||| NN
( ||| S:1426 E:1427 ||| -LRB-
aOR ||| S:1427 E:1430 ||| NNP
)  ||| S:1430 E:1432 ||| -RRB-
2.33 ||| S:1432 E:1436 ||| CD
,  ||| S:1436 E:1438 ||| ,
95 ||| S:1438 E:1440 ||| CD
%  ||| S:1440 E:1442 ||| NN
CI  ||| S:1442 E:1445 ||| NNP
1.02-5.32 ||| S:1445 E:1454 ||| NNP
] ||| S:1454 E:1455 ||| -RRB-
.  ||| S:1455 E:1457 ||| .
Compared  ||| S:1457 E:1466 ||| VBN
to  ||| S:1466 E:1469 ||| TO
MSM  ||| S:1469 E:1473 ||| NNP
without  ||| S:1473 E:1481 ||| IN
HIV  ||| S:1481 E:1485 ||| NNP
infection ||| S:1485 E:1494 ||| NN
,  ||| S:1494 E:1496 ||| ,
MSM  ||| S:1496 E:1500 ||| NNP
living  ||| S:1500 E:1507 ||| NN
with  ||| S:1507 E:1512 ||| IN
HIV  ||| S:1512 E:1516 ||| NNP
were  ||| S:1516 E:1521 ||| VBD
more  ||| S:1521 E:1526 ||| RBR
likely  ||| S:1526 E:1533 ||| JJ
to  ||| S:1533 E:1536 ||| TO
have  ||| S:1536 E:1541 ||| VB
ever  ||| S:1541 E:1546 ||| RB
accessed  ||| S:1546 E:1555 ||| VB
a  ||| S:1555 E:1557 ||| DT
health  ||| S:1557 E:1564 ||| NN
service  ||| S:1564 E:1572 ||| NN
targeting  ||| S:1572 E:1582 ||| VBG
MSM  ||| S:1582 E:1586 ||| NNP
in  ||| S:1586 E:1589 ||| IN
Douala  ||| S:1589 E:1596 ||| NNP
( ||| S:1596 E:1597 ||| -LRB-
aOR  ||| S:1597 E:1601 ||| NNP
4.88 ||| S:1601 E:1605 ||| NNP
,  ||| S:1605 E:1607 ||| ,
95 ||| S:1607 E:1609 ||| CD
%  ||| S:1609 E:1611 ||| NN
CI  ||| S:1611 E:1614 ||| NNP
1.63-14.63 ||| S:1614 E:1624 ||| NNP
) ||| S:1624 E:1625 ||| -RRB-
.  ||| S:1625 E:1627 ||| .
In  ||| S:1627 E:1630 ||| IN
Yaoundé ||| S:1630 E:1637 ||| NNP
,  ||| S:1637 E:1639 ||| ,
MSM  ||| S:1639 E:1643 ||| NNP
living  ||| S:1643 E:1650 ||| NN
with  ||| S:1650 E:1655 ||| IN
HIV  ||| S:1655 E:1659 ||| NNP
were  ||| S:1659 E:1664 ||| VBD
more  ||| S:1664 E:1669 ||| RBR
likely  ||| S:1669 E:1676 ||| JJ
to  ||| S:1676 E:1679 ||| TO
use  ||| S:1679 E:1683 ||| VB
CCLs  ||| S:1683 E:1688 ||| JJ
( ||| S:1688 E:1689 ||| -LRB-
aOR  ||| S:1689 E:1693 ||| NNP
2.44 ||| S:1693 E:1697 ||| CD
,  ||| S:1697 E:1699 ||| ,
95 ||| S:1699 E:1701 ||| CD
%  ||| S:1701 E:1703 ||| NN
CI  ||| S:1703 E:1706 ||| NNP
1.19-4.97 ||| S:1706 E:1715 ||| NNP
) ||| S:1715 E:1716 ||| -RRB-
.  ||| S:1716 E:1718 ||| .
High  ||| S:1718 E:1723 ||| NNP
HIV  ||| S:1723 E:1727 ||| NNP
prevalence  ||| S:1727 E:1738 ||| NN
were  ||| S:1738 E:1743 ||| VBD
observed  ||| S:1743 E:1752 ||| VBN
and  ||| S:1752 E:1756 ||| CC
condoms  ||| S:1756 E:1764 ||| NNS
and  ||| S:1764 E:1768 ||| CC
CCLs  ||| S:1768 E:1773 ||| NNP
were  ||| S:1773 E:1778 ||| VBD
used  ||| S:1778 E:1783 ||| VBN
inconsistently  ||| S:1783 E:1798 ||| VBN
indicating  ||| S:1798 E:1809 ||| VBG
that  ||| S:1809 E:1814 ||| IN
MSM  ||| S:1814 E:1818 ||| NNP
are  ||| S:1818 E:1822 ||| VBP
a  ||| S:1822 E:1824 ||| DT
priority  ||| S:1824 E:1833 ||| NN
population  ||| S:1833 E:1844 ||| NN
for  ||| S:1844 E:1848 ||| IN
HIV  ||| S:1848 E:1852 ||| NNP
prevention ||| S:1852 E:1862 ||| NN
,  ||| S:1862 E:1864 ||| ,
treatment  ||| S:1864 E:1874 ||| NN
and  ||| S:1874 E:1878 ||| CC
care  ||| S:1878 E:1883 ||| NN
services  ||| S:1883 E:1892 ||| NNS
in  ||| S:1892 E:1895 ||| IN
Douala  ||| S:1895 E:1902 ||| NNP
and  ||| S:1902 E:1906 ||| CC
Yaoundé ||| S:1906 E:1913 ||| NNP
.  ||| S:1913 E:1915 ||| .
Building  ||| S:1915 E:1924 ||| VBG
the  ||| S:1924 E:1928 ||| DT
capacity  ||| S:1928 E:1937 ||| NN
of  ||| S:1937 E:1940 ||| IN
MSM  ||| S:1940 E:1944 ||| NNP
community  ||| S:1944 E:1954 ||| NN
organizations  ||| S:1954 E:1968 ||| NNS
and  ||| S:1968 E:1972 ||| CC
improving  ||| S:1972 E:1982 ||| VBG
the  ||| S:1982 E:1986 ||| DT
delivery  ||| S:1986 E:1995 ||| NN
and  ||| S:1995 E:1999 ||| CC
scale-up  ||| S:1999 E:2008 ||| JJ
of  ||| S:2008 E:2011 ||| IN
multimodal  ||| S:2011 E:2022 ||| JJ
interventions  ||| S:2022 E:2036 ||| NNS
for  ||| S:2036 E:2040 ||| IN
MSM  ||| S:2040 E:2044 ||| NNP
that  ||| S:2044 E:2049 ||| WDT
are  ||| S:2049 E:2053 ||| VBP
sensitive  ||| S:2053 E:2063 ||| JJ
to  ||| S:2063 E:2066 ||| TO
concerns  ||| S:2066 E:2075 ||| NNS
about  ||| S:2075 E:2081 ||| IN
confidentiality  ||| S:2081 E:2097 ||| NN
and  ||| S:2097 E:2101 ||| CC
the  ||| S:2101 E:2105 ||| DT
complex  ||| S:2105 E:2113 ||| JJ
individual ||| S:2113 E:2123 ||| NN
,  ||| S:2123 E:2125 ||| ,
social ||| S:2125 E:2131 ||| JJ
,  ||| S:2131 E:2133 ||| ,
community-level  ||| S:2133 E:2149 ||| JJ
and  ||| S:2149 E:2153 ||| CC
policy  ||| S:2153 E:2160 ||| NN
challenges  ||| S:2160 E:2171 ||| NNS
are  ||| S:2171 E:2175 ||| VBP
needed  ||| S:2175 E:2182 ||| VBN
to  ||| S:2182 E:2185 ||| TO
successfully  ||| S:2185 E:2198 ||| RB
engage  ||| S:2198 E:2205 ||| VB
young  ||| S:2205 E:2211 ||| JJ
MSM  ||| S:2211 E:2215 ||| NN
in  ||| S:2215 E:2218 ||| IN
the  ||| S:2218 E:2222 ||| DT
continuum  ||| S:2222 E:2232 ||| NN
of  ||| S:2232 E:2235 ||| IN
HIV  ||| S:2235 E:2239 ||| NNP
care ||| S:2239 E:2243 ||| NN
.  ||| S:2243 E:2245 ||| .
In  ||| S:2245 E:2248 ||| IN
addition  ||| S:2248 E:2257 ||| NN
to  ||| S:2257 E:2260 ||| TO
scaling  ||| S:2260 E:2268 ||| VB
up  ||| S:2268 E:2271 ||| RP
condom  ||| S:2271 E:2278 ||| NN
and  ||| S:2278 E:2282 ||| CC
CCL  ||| S:2282 E:2286 ||| NNP
access ||| S:2286 E:2292 ||| NN
,  ||| S:2292 E:2294 ||| ,
evaluating  ||| S:2294 E:2305 ||| VBG
the  ||| S:2305 E:2309 ||| DT
feasibility  ||| S:2309 E:2321 ||| NN
of  ||| S:2321 E:2324 ||| IN
novel  ||| S:2324 E:2330 ||| JJ
biomedical  ||| S:2330 E:2341 ||| JJ
interventions ||| S:2341 E:2354 ||| NNS
,  ||| S:2354 E:2356 ||| ,
including  ||| S:2356 E:2366 ||| VBG
antiretroviral  ||| S:2366 E:2381 ||| JJ
pre-exposure  ||| S:2381 E:2394 ||| JJ
prophylaxis  ||| S:2394 E:2406 ||| NN
and  ||| S:2406 E:2410 ||| CC
early  ||| S:2410 E:2416 ||| JJ
antiretroviral  ||| S:2416 E:2431 ||| JJ
therapy  ||| S:2431 E:2439 ||| NN
for  ||| S:2439 E:2443 ||| IN
MSM  ||| S:2443 E:2447 ||| NNP
living  ||| S:2447 E:2454 ||| NN
with  ||| S:2454 E:2459 ||| IN
HIV  ||| S:2459 E:2463 ||| NNP
in  ||| S:2463 E:2466 ||| IN
Cameroon ||| S:2466 E:2474 ||| NNP
,  ||| S:2474 E:2476 ||| ,
is  ||| S:2476 E:2479 ||| VBZ
also  ||| S:2479 E:2484 ||| RB
warranted ||| S:2484 E:2493 ||| VBN
.  ||| S:2493 E:2495 ||| .
